GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
- B2240 OlanzapineTarget: 5-HT2 Receptors|D2 ReceptorsSummary: Antagonist of 5-HT2A and dopamine D2 receptors
- B1199 TandospironeSummary: Anxiolytic and antidepressant reagent
- B1628 MPEPSummary: MGlu5 receptor antagonist
- B1926 Dexamethasone acetateTarget: Glucocorticoid Receptors|interleukin receptorSummary: IL Receptor modulator
- B2218 Azilsartan MedoxomilSummary: Angiotensin II receptor type 1 antagonist
- B2210 AzilsartanTarget: Angiotensin AT1 ReceptorsSummary: Potent angiotensin II type 1 (AT1) receptor inverse agonist
- B1283 Prasugrel hydrochlorideSummary: P2 Receptor inhibitor
- B1535 OC000459Summary: Antagonist of D prostanoid receptor 2 ,potent and selective
- B2254 SB269970 HClSummary: 5-HT7 receptor antagonist,potent and selective
- B1629 VU 0357121Summary: Novel positive allosteric modulator (PAM) of mGlu5